| Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ... New England Journal of Medicine 378 (6), 518-528, 2018 | 967 | 2018 |
| Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia OC Goodyear, M Dennis, NY Jilani, J Loke, S Siddique, G Ryan, ... Blood, blood-2011-09-377044, 2012 | 437 | 2012 |
| Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial MV Mateos, M Cavo, J Blade, MA Dimopoulos, K Suzuki, A Jakubowiak, ... The Lancet 395 (10218), 132-141, 2020 | 393 | 2020 |
| How I treat monoclonal gammopathy of renal significance (MGRS) JP Fermand, F Bridoux, RA Kyle, E Kastritis, BM Weiss, MA Cook, ... Blood, blood-2013-05-495929, 2013 | 359 | 2013 |
| Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies CA Hutchison, P Cockwell, S Reid, K Chandler, GP Mead, J Harrison, ... Journal of the American Society of Nephrology 18 (3), 886-895, 2007 | 347 | 2007 |
| Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis CA Hutchison, AR Bradwell, M Cook, K Basnayake, S Basu, S Harding, ... Clinical Journal of the American Society of Nephrology 4 (4), 745-754, 2009 | 335 | 2009 |
| Early reduction of serum-free light chains associates with renal recovery in myeloma kidney CA Hutchison, P Cockwell, S Stringer, A Bradwell, M Cook, MA Gertz, ... Journal of the American Society of Nephrology, ASN. 2010080857, 2011 | 288 | 2011 |
| Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in … S Tauro, C Craddock, K Peggs, G Begum, P Mahendra, G Cook, J Marsh, ... Journal of Clinical Oncology 23 (36), 9387-9393, 2005 | 270 | 2005 |
| The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia MA Cook, DW Milligan, CD Fegan, PJ Darbyshire, P Mahendra, ... Blood 103 (4), 1521-1526, 2004 | 231 | 2004 |
| Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation M Cook, D Briggs, C Craddock, P Mahendra, D Milligan, C Fegan, ... Blood 107 (3), 1230-1232, 2006 | 227 | 2006 |
| A phase 2 study of SRT 501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma R Popat, T Plesner, F Davies, G Cook, M Cook, P Elliott, E Jacobson, ... British journal of haematology 160 (5), 714-717, 2013 | 214 | 2013 |
| Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis CA Hutchison, N Heyne, P Airia, R Schindler, D Zickler, M Cook, ... Nephrology Dialysis Transplantation 27 (10), 3823-3828, 2012 | 174 | 2012 |
| European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial CA Hutchison, M Cook, N Heyne, K Weisel, L Billingham, A Bradwell, ... Trials 9 (1), 55, 2008 | 143 | 2008 |
| High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial CA Hutchison, P Cockwell, V Moroz, AR Bradwell, L Fifer, JD Gillmore, ... The Lancet Haematology 6 (4), e217-e228, 2019 | 122 | 2019 |
| Current trends of renal impairment in multiple myeloma P Yadav, M Cook, P Cockwell Kidney Diseases 1 (4), 241-257, 2015 | 116 | 2015 |
| Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT B Pourgheysari, KP Piper, A McLarnon, J Arrazi, R Bruton, F Clark, ... Bone marrow transplantation 43 (11), 853, 2009 | 98 | 2009 |
| Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia C Craddock, S Nagra, A Peniket, C Brookes, L Buckley, E Nikolousis, ... Haematologica 95 (6), 989-995, 2010 | 87 | 2010 |
| Donor HLA‐C genotype has a profound impact on the clinical outcome following liver transplantation R Hanvesakul, N Spencer, M Cook, B Gunson, M Hathaway, R Brown, ... American Journal of Transplantation 8 (9), 1931-1941, 2008 | 74 | 2008 |
| SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex PJ Norman, MA Cook, BS Carey, CVF Carrington, DH Verity, K Hameed, ... Immunogenetics 56 (4), 225-237, 2004 | 71 | 2004 |
| Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma OC Goodyear, G Pratt, A McLarnon, M Cook, K Piper, P Moss Blood 112 (8), 3362-3372, 2008 | 69 | 2008 |
